What is GlucoTrack, Inc. (GCTK) stock price today?

GlucoTrack, Inc. (GCTK) is currently trading at $0.29, up 0.03% today.

What is GCTK P/E ratio?

GlucoTrack, Inc.'s P/E ratio is -0.05. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GCTK return on equity (ROE)?

GlucoTrack, Inc.'s return on equity (ROE) is -581.98%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GlucoTrack, Inc.'s market cap?

GlucoTrack, Inc. has a market capitalization of $165300.

NASDAQ · Medical - Instruments & Supplies

GlucoTrack, Inc. (GCTK) Stock

$0.29 +0.03% NASDAQ: GCTK Healthcare

Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems.

Valuation

Metric	Value
Price	$0.29
Market Cap	$165300
P/E Ratio	-0.05
P/B Ratio	-0.56
P/S Ratio	0.00
EPS (TTM)	$-21.56
52-Week High	$14.14
52-Week Low	$0.29
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-581.98%
ROA	-387.72%
ROCE	-533.33%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.03
Current Ratio	1.60

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-4.0M	$-4.0M	$-7.0M	$-15.0M	$-16.0M
Net Profit	$-4.0M	$-4.0M	$-7.0M	$-23.0M	$-19.0M
EPS	$-26.32	$-28.66	$-38.30	$60.76	$-21.56
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$6.0M	$2.0M	$5.0M	$6.0M	$8.0M
Total Liabilities	$1.0M	$1.0M	$2.0M	$19.0M	$5.0M
Cash	$6.0M	$2.0M	$4.0M	$6.0M	$7.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing GlobeNewswire · Jul 17, 2026 Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives GlobeNewswire · Jul 17, 2026 UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform GlobeNewswire · Jul 16, 2026 Glucotrack Completes Lōkahi Therapeutics Business Combination, Creating AI-Driven Healthcare Platform InvestorsHub · Jul 15, 2026 BC-Most Active Stocks Associated Press · Jul 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-4.0M	$-4.0M	$-7.0M	$-12.0M	$-15.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-4.0M	$-4.0M	$2.0M	$1.0M	$2.0M
Free Cash Flow	$-4.0M	$-4.0M	$-7.0M	$-13.0M	$-15.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.22
FCF Yield	-9074.41%
Quick Ratio	1.60
Interest Coverage	-65.42
Return 1Y	-90.29%
Return 3Y	-99.98%
Return 5Y	-100.00%

Ownership

Insiders Held0.76%

Institutions Held3.72%

Institutions Float Held3.75%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About GlucoTrack, Inc.

Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.

GlucoTrack, Inc. is led by CEO Paul V. Goode, employs 11 people, headquartered in IL, publicly traded since 2013.

GlucoTrack, Inc. (GCTK) stock trades at $0.29 with a market capitalization of $165300. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of -0.56, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.29 and $14.14, and currently trades 97.9% below its 52-week high.

On profitability, GlucoTrack, Inc. generates a return on equity (ROE) of -581.98%, return on capital employed of -533.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.glucotrack.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides